This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

ASCP Corner

Clinical Psychopharmacology of Pediatric Mood Stabilizer and Antipsychotic Treatment, Part 1: Challenges and Developments

Christoph U. Correll, MD

Published: August 15, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The field of clinical psychopharmacology has a long and productive history. Only recently, however, has the field begun to include children and adolescents on a larger scale. Reasons for this delay include concerns about safety and tolerability in this vulnerable population, diagnostic uncertainties, and the reluctance of the industry to embark on pediatric registration and labeling studies for diagnoses that traditionally have not been seen as predominant disorders of childhood and adolescence.’ ‹

Volume: 68

Quick Links: Child and Adolescent , Populations

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived...

Read More...